日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).

癌症免疫治疗学会:多重免疫组织化学/免疫荧光检测报告标准(STORMI)。

Sater Sam, Bifulco Carlo B, Rodriguez-Canales Jaime, Yeong Joe, Akturk Guray, Angelo Michael, Ballesteros-Merino Carmen, Bankhead Peter, Basu Subham, Blando Jorge M, Brajkovic Saska, Cassano Marco, Chen Benjamin J, Coskun Ahmet F, Cottrell Tricia R, De Andrea Carlos E, Edwards Robin H, Egelston Colt, Engle Logan L, Ernstoff Marc S, Fan Rong, Feldman Michael, Fox Bernard A, Galon Jerome, Gartrell Robyn, Gnjatic Sacha, Green Benjamin F, Gulley James L MD, Hellebust Anne, Hewitt Stephen, Hollmann Travis J, Horn Lucas A, Howat William J, Hoyt Clifford C, Jensen Shawn M, Kulasinghe Arutha, Lassoued Wiem, Lott Steven, Mansfield James, Marwitz Sebastian, Netto George, Page David B, Parra Edwin, Rimm David L, Rodig Scott J, Salgado Roberto, Schapiro Denis, Schalper Kurt A MD, Sunshine Joel C, Surace Michael J, Szalay Alexander S, Thurin Magdalena, Villasboas Jose C, Wharton Keith, Wistuba Ignacio I, Yearley Jennifer H, Yuan Yinyin, Zaki Geroge, Ziai James, Taube Janis M

Degradation of CDK9 by Ubiquitin E3 Ligase STUB1 Regulates P-TEFb Level and Its Functions for Global Target Gene Expression within Mammalian Cells.

泛素 E3 连接酶 STUB1 对 CDK9 的降解调节 P-TEFb 水平及其在哺乳动物细胞内全局靶基因表达中的功能

Basu Subham, Nandy Arijit, Ghosh Avik, Mall Dheerendra Pratap, Biswas Debabrata

The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis

培门冬酶与天然门冬酰胺酶一线治疗急性淋巴细胞白血病的成本效益分析:一项基于英国的成本效用分析

Hu, Xingdi; Wildman, Kingsley P; Basu, Subham; Lin, Peggy L; Rowntree, Clare; Saha, Vaskar